highlights the benefits of efficient authorisation, including more timely access to PPPs including low risk alternatives;
poudarja koristi učinkovite odobritve, vključno z bolj pravočasnim dostopom do fitofarmacevtskih sredstev in alternativ z majhnim tveganjem;